Companies partner to develop immunology-based cancer therapies
- The GSK/Adaptimmune partnership will focus on developing treatments for multiple myeloma and other cancers.
- The main target will be T cell receptors.
- Clinical proof of concept is anticipated by 2016.
The collaboration between the two companies will focus on developing therapies not only for multiple myeloma, but also for melanoma, sarcoma and ovarian cancer. Adaptimmune could gross $350 million over a 7-year period.
- http://www.worldpharmanews.com GSK signs Adaptimmune deal